Full-Time
Associate Director
US Omnichannel/Digital Engagement
Updated on 9/3/2026
Biogen
5,001-10,000 employees
Develops therapies for neurological disorders
Compensation Overview
$164k - $226k/yr
No H1B Sponsorship
Cambridge, MA, USA
Hybrid
Three days on-site per week required.
Bachelor's, MBA
 Growth & Marketing (1) |
|---|
Get referred to Biogen
See people who can refer or advise you
- A minimum of 7 years of omnichannel or digital engagement healthcare client experience focused on strategy, planning, execution, and measurement in pharmaceutical or biotechnology environments.
- Proven ability to design and evolve omnichannel engagement strategies for existing brands, including customer journeys, channel mix, and content sequencing.
- Strong capability to own strategy-to-execution for assigned brands, ensuring alignment between engagement design, delivery, and performance.
- Working knowledge of AI-driven next-best-action, personalization, and orchestration frameworks, with the ability to apply insights to strategy and optimization.
- Experience serving as a trusted omnichannel partner to Brand teams and influencing engagement decisions within established brand strategy guardrails.
- Hands-on ownership of omnichannel campaign planning, execution, monitoring, and optimization across the brand lifecycle.
- Experience translating omnichannel strategies into actionable operational requirements within marketing technology ecosystems.
- Ability to collaborate with Media, Omnichannel Operations, Decision Science, Information Technology, and compliance partners.
- Comfort interpreting performance data and analytics to inform strategic refinements and ongoing optimization.
- Strong understanding of regulatory, privacy, and promotional review committee requirements as applied to omnichannel engagement.
- A Bachelor of Arts or Bachelor of Science degree is required.
- Serve as the omnichannel and digital subject matter expert and Experience Architect for assigned Therapeutic Areas.
- Translate Brand objectives into orchestrated, AI-enabled customer journeys spanning awareness through engagement and conversion.
- Design engagement flows that leverage next-best-action recommendations across customer, channel, content, and cadence.
- Ensure omnichannel strategies are insight-driven, compliant, measurable, and aligned to Brand and portfolio priorities.
- Ensure orchestration aligns to Brand funnels while maintaining agility as insights and performance evolve.
- Act as the single, primary omnichannel point of contact for the Brand, owning end-to-end strategy and execution.
- Guide Brand teams on experience design, channel appropriateness, content sequencing, and omnichannel investment decisions.
- Facilitate regular engagement planning sessions with Brand teams to align on campaign objectives, content strategy, and optimization opportunities.
- Provide ongoing thought leadership through performance insights, learning agendas, and strategic recommendations.
- Support the evolution of Biogen’s commercial model toward a fully integrated, AI-enabled omnichannel approach.
- Own end-to-end accountability for omnichannel campaign planning, execution, performance, and optimization.
- Ensure Media strategies are fully integrated into omnichannel experience design.
- Collaborate with Media, Omnichannel Operations, Decision Science, and Information Technology teams to ensure high-quality, on-time, and compliant execution.
- Translate experience designs into clear business and operational requirements prioritized through SAFE and Agile delivery processes.
- Ensure adherence to omnichannel playbooks, standard operating procedures, and enterprise standards for scalability and consistency.
- Serve as the Therapeutic Area expert on Biogen’s marketing technology ecosystem and AI-driven orchestration tools.
- Champion adoption of omnichannel capabilities and ways of working in partnership with the Operations team.
- Take end-to-end accountability for campaign execution in partnership with the Operations team.
- Take full responsibility for omnichannel impact against Brand objectives.
- Partner with Decision Sciences to interpret AI-driven insights and refine next-best-action logic.
- Champion tagging, tracking, and reporting readiness from the outset of planning.
- Drive continuous optimization through testing and insight-led refinements.
- Maintain a strong understanding of next-generation omnichannel engagement, including AI-driven personalization and automation.
- Stay ahead of digital and AI trends, emerging channels, and evolving best practices across healthcare professional and patient engagement.
- A Master of Business Administration is preferred.
- Experience working with next-generation omnichannel engagement, AI-driven personalization and automation, emerging channels, and evolving best practices across healthcare professional and patient engagement.
Biogen is a global biotechnology company focused on neuroscience. It discovers, develops, and delivers therapies for neurological disorders, such as multiple sclerosis and other neurodegenerative diseases. Its product process starts with research and development to identify potential drugs, followed by clinical testing and regulatory approval, ultimately leading to commercialization and patient treatment. Biogen differentiates itself through a long history (founded in 1978), a deep specialization in neuroscience, and an integrated pipeline that moves ideas from discovery to approved medicines, aiming to create value for shareholders while helping communities. The company’s goal is to advance therapies for neurological diseases to improve patients’ lives and generate sustainable value for stakeholders.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
1978
Get referred to Biogen
See people who can refer or advise you
Simplify's Take
What believers are saying
- Second-quarter 2026 revenue rose to $2.74 billion, and sales outlook turned mid-single-digit growth.
- Leqembi subcutaneous launch on July 13, 2026 reduces clinic burden and expands access.
- Newer medicines outearned the MS franchise in 2026, showing portfolio transition momentum.
What critics are saying
- Eli Lilly's Kisunla pressures Leqembi pricing, convenience, and Alzheimer's share in 2026.
- Biogen cut 2026 EPS guidance after Apellis integration charges, financing costs, and milestones.
- Any EMPEROR failure for zorevunersen in 2027 would weaken Biogen's neurology growth story.
What makes Biogen unique
- Leqembi with Eisai gained U.S. subcutaneous initiation approval on July 13, 2026.
- Biogen sells approved growth drugs beyond neuroscience: Skyclarys, Zurzuvae, Empaveli, Syfovre.
- Biogen completed RayThera on August 6, 2026, strengthening immunology pipeline depth.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Professional Development Budget
Growth & Insights and Company News
6 month growth
↓ -10%1 year growth
↓ -10%2 year growth
↓ -10%Eisai and Biogen announced that China's National Medical Products Administration approved the subcutaneous formulation of LEQEMBI (lecanemab) for early Alzheimer's disease. This marks the first anti-amyloid therapy in China enabling at-home administration. The approved regimen involves 500mg given once weekly as two consecutive 250mg injections using an autoinjector. The application received priority review designation after submission in January 2026. Launch is planned during Eisai's fiscal year ending March 31, 2027. The subcutaneous formulation takes approximately 15 seconds per injection, significantly reducing time compared with intravenous infusions. Patients can administer treatment at home weekly, or alternatively receive intravenous administration every two weeks in hospital settings. Switching between administration methods is permitted during treatment. The approval aims to reduce clinic visit burden for patients and caregivers whilst potentially decreasing healthcare resources associated with intravenous dosing.
Stoke Therapeutics and Biogen to present four-year zorevunersen data at epilepsy congress. Fiona Craig Updated Tue, September 1, 2026 at 7:00 AM PDT Stoke Therapeutics (NASDAQ:STOK) and Biogen (NASDAQ:BIIB) said they will present clinical data for zorevunersen, their investigational treatment for Dravet syndrome, at the 16th European Epilepsy Congress in Athens, Greece, from September 5 to 9. The presentations will include the first disclosure at a medical meeting of four-year results from ongoing Phase 1/2a open-label extension studies. According to the companies, improvements in cognition and behaviour were sustained through four years alongside reductions in seizures and a generally well-tolerated safety profile. New sub-analyses will also examine the treatment's effects on the most severe seizure types and patient quality of life. These findings are based on company-reported clinical data and zorevunersen remains investigational. Majority of patients remain in extension studies. A total of 81 patients were enrolled in the Phase 1/2a studies, with 93% subsequently continuing into one of two open-label extension studies. At the four-year data cutoff, 77% of those patients remained enrolled. More than 930 doses of zorevunersen had been administered as of July 31, 2026. Elevated cerebrospinal fluid protein levels were observed in approximately 94% of patients, with 59% classified as treatment-emergent adverse events. According to Stoke and Biogen, no serious clinical manifestations or cases of hydrocephalus were reported. The clinical significance of the reported findings remains subject to further evaluation, including results from ongoing late-stage development. Zorevunersen targets the SCN1A gene. Zorevunersen is an antisense oligonucleotide designed to increase production of functional NaV1.1 protein by targeting the unaffected copy of the SCN1A gene. Mutations in SCN1A are associated with most cases of Dravet syndrome. The investigational therapy has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, as well as orphan drug designation from both the FDA and the European Medicines Agency. These designations are intended to support the development of qualifying treatments and do not constitute regulatory approval. Phase 3 EMPEROR study underway. Stoke Therapeutics and Biogen are currently evaluating zorevunersen in the global Phase 3 EMPEROR study, with results anticipated in the third quarter of 2027. The timing represents the companies' current expectation and remains subject to the progress of the clinical trial. Under the companies' collaboration agreement, Stoke retains commercialization rights for zorevunersen in the United States, Canada and Mexico, while Biogen holds exclusive rights in the rest of the world. Zorevunersen has not been approved by any regulatory authority, and its safety and efficacy remain under clinical investigation. Stoke Therapeutics stock price Biogen stock price
Josh Brown, CEO of Ritholtz Wealth Management, named Incyte and Biogen as top healthcare stock picks on CNBC's Halftime Report. Brown said he wanted to highlight stocks unrelated to AI and data centre spending themes. Incyte, up 22% this year, develops drugs for blood cancers, solid tumours and inflammatory skin diseases. In July, revenue rose 38% year over year whilst net product sales jumped 40%, both beating Wall Street estimates. Its key product Jakafi saw sales increase 7%, whilst skin cream Opzelura's sales rose 24%. The company expects about 10 clinical data readouts in the second half of fiscal 2026. It raised full-year fiscal 2026 sales guidance by 7% and lifted Opzelura outlook by roughly 40%.
Josh Brown says 'take a break from AI capex world,' highlights his 2 top healthcare stock picks. Published on august 30, 2026 at 9:45 am by fahad saleem in hedge funds, news, stock analysis. In a recent interview on CNBC's Halftime Report, Josh Brown, CEO of Ritholtz Wealth Management, highlighted Incyte (NASDAQ: INCY) and Biogen (NASDAQ: BIIB) as two of his "Best Stocks in the Market." Brown said he wanted to focus on stocks that had "nothing to do" with the AI and data-center spending theme. "We wanted to do something that had nothing to do with data centers and GPUs and just take a break from that whole AI capex world that we've been living in for so long," Brown said. "We wanted to talk about stocks that are working away from that." Brown likes Biogen because of strong fundamentals and the company's strong earnings performance. But in this article, we will focus on Incyte, which is up 22% so far this year. Analyzing Incyte. Brown's bullish case for Incyte centers on its strong earnings momentum and expanding drug pipeline. Brown said the company has a pipeline of roughly nine or 10 drugs at various stages of development, creating multiple potential catalysts for future growth. Incyte Corporation (NASDAQ:INCY) develops drugs for blood cancers, solid tumors and inflammatory skin diseases. In the quarterly results reported in July, revenue rose 38% year over year and net product sales jumped 40%. Both metrics beat Wall Street estimates. Its key product is Jakafi, a pill that treats two blood cancers and a complication of bone marrow transplants. Jakafi sales rose 7% in the quarter, and the number of prescriptions filled rose 9%. Opzelura, a skin cream, saw sales rise 24% after removing one-time benefits. Bulls point to how diversified the company has become. Even when Jakafi loses exclusivity, the company is on track to reach $3 billion to $4 billion in net sales by 2030 from the rest of the portfolio. The company also raised its full-year fiscal 2026 sales guidance by about 7% and lifted the Opzelura outlook by roughly 40%. The company expects about 10 clinical data readouts in the second half of fiscal 2026, four of them from registrational trials, which could be strong catalysts. Bears point to Jakafi, which still accounts for a major chunk of net sales and could lose exclusivity in key regions in 2028. A lot depends on new launches and catalysts landing before then. Competition is coming. AbbVie recently won European Commission approval for Rinvoq in non-segmental vitiligo, which could put direct pressure on Opzelura's European vitiligo business.
Eisai, Biogen launch at-home Leqembi autoinjector in the US for early Alzheimer's. Eisai and Biogen announced that LEQEMBI IQLIK (lecanemab-irmb) autoinjector is now available in the U.S. for initiation of therapy in adults with mild cognitive impairment or mild dementia due to Alzheimer's disease, collectively referred to as early AD. For initiation, the approved regimen is 500 mg once weekly delivered as two consecutive 250 mg subcutaneous injections, each administered in approximately 15 seconds; maintenance dosing may be 360 mg once weekly after 18 months of intravenous or subcutaneous treatment, and patients may begin with or switch between IV infusion and subcutaneous autoinjector administration. The company claims at-home dosing may reduce clinic time and healthcare resource use. Support resources announced include an instructions for use video, a welcome kit, the LEQEMBI Companion app, specialty pharmacy network services and financial assistance for eligible patients. Baseline and periodic MRI monitoring for amyloid-related imaging abnormalities is recommended and prescribing information lists ARIA and infusion-related risks to consider.